Back to top

MTN-017 was a Phase II trial designed to evaluate the rectal safety, drug absorption and acceptability of a reduced glycerin formulation of tenofovir gel, as well as oral Truvada as daily oral PrEP, at sites in Peru, South Africa, Thailand and the U.S., including Puerto Rico. The study enrolled 195 cisgender men and transgender women who have sex with men. Results, which were reported February 2016, found the gel was safe to use, with participants preferring to use the gel around the time of sex as opposed to daily, but that they were also more likely to use daily oral PrEP than a daily gel.


International Study Finds High Levels of Adherence to Use of Rectal Microbicide Gel



MTN-017 Backgrounder



MTN-017 Q&A



See Also

MTN-017 Study Protocol


MTN-017 Study Page


Rectal Microbicides – Fact Sheet



International Study Finds Rectal Microbicide Gel Safe When Used Daily and With Sex



VIDEO – The Rectal Revolution is Here


Other Study Milestones

Researchers Launch First-Ever Phase II Safety Study of a Rectal Microbicide to Prevent HIV



Gel Safe and Acceptable as Approach to Preventing HIV from Anal Sex in Early Phase Clinical Trial



MTN and Partners Launch “The Rectal Revolution Is Here: An Introduction to Rectal Microbicide Clinical Trials”



Reduced Glycerin Formulation of Tenofovir Vaginal Gel Safe for Rectal Use



Rectal Formulation of Tenofovir Gel Found Safe and Acceptable in Early Phase Clinical Study